https://www.selleckchem.com/pr....oducts/pifithrin-alp
To evaluate the inhibitory interaction of thymohydroquinone against blood-brain barrier (BB-associated neuropsychiatric and neurodegenerative disorders. An elaborated study was designed to evaluate the interaction of thymohydroquinone with BBB-disrupting proteins and to highlight its pharmacokinetic and safety attributes. Thymohydroquinone demonstrated stable interaction with BBB-disrupting protein active site with Ki (inhibition constant) ranges of (2.71mM-736.15μM), binding energy (-4.3 to5.6Kcal/mol), ligand efficiency (-0.
Like
Comment
Share
